바이러스 벡터 생산 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global viral vector production market size is expected to reach USD 13.28 Billion in 2034 from USD 2.76 Billion in 2025, growing at a CAGR of 19.06% during 2026-2034.The Global Viral Vector Production Market is witnessing rapid expansion driven by the surge in gene therapy, cell therapy, and vaccine development programs. Viral vectors are critical components in delivering genetic material into cells, making them indispensable in advanced biopharmaceutical research. Increasing clinical trials and regulatory approvals for gene-based therapies are significantly boosting production demand.

Growth drivers include technological advancements in vector engineering, improved scalability of manufacturing processes, and strong investments from pharmaceutical companies. The rising prevalence of rare genetic disorders and cancer further supports market expansion. Additionally, government funding and strategic collaborations between biotech firms and contract development organizations enhance production capacity worldwide.

Looking ahead, the market is expected to grow at an accelerated pace as personalized medicine gains mainstream acceptance. Automation, modular manufacturing facilities, and innovations in upstream and downstream processing will improve efficiency and reduce costs. As regulatory frameworks evolve to support advanced therapies, viral vector production will remain a cornerstone of next-generation biopharmaceutical development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

• Cancer
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By Application

• Gene Therapy
• Vaccinology

By Viral Vector Type

• Adenoviral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adeno-Associated Viral Vectors
• Other Viral Vectors

COMPANIES PROFILED

• Thermo Fisher Scientific, Lonza, Catalent, Charles River Laboratories, WuXi AppTec, WuXi Advanced Therapies, Viralgen, Fujifilm Diosynth Biotechnologies, Oxford Biomedica, Brammer Bio, Andelyn Biosciences, Forge Biologics, ElevateBio BaseCamp, Genezen Laboratories, Batavia Biosciences, Vibalogics, YposKesi, FinVector, Resilience, Novartis Gene Therapies

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY VIRAL VECTOR TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Viral Vector Type
• 6.2. Adenoviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lentiviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Retroviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Adeno-Associated Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Indication
  • 7.2.2 By Application
  • 7.2.3 By Viral Vector Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Indication
  • 7.3.2 By Application
  • 7.3.3 By Viral Vector Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Indication
  • 7.4.2 By Application
  • 7.4.3 By Viral Vector Type
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Indication
  • 7.5.2 By Application
  • 7.5.3 By Viral Vector Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Indication
  • 7.6.2 By Application
  • 7.6.3 By Viral Vector Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VIRAL VECTOR PRODUCTION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Thermo Fisher Scientific
  • 9.2.2 Lonza
  • 9.2.3 Catalent
  • 9.2.4 Charles River Laboratories
  • 9.2.5 WuXi AppTec
  • 9.2.6 WuXi Advanced Therapies
  • 9.2.7 Viralgen
  • 9.2.8 Fujifilm Diosynth Biotechnologies
  • 9.2.9 Oxford Biomedica
  • 9.2.10 Brammer Bio
  • 9.2.11 Andelyn Biosciences
  • 9.2.12 Forge Biologics
  • 9.2.13 ElevateBio BaseCamp
  • 9.2.14 Genezen Laboratories
  • 9.2.15 Batavia Biosciences
  • 9.2.16 Vibalogics
  • 9.2.17 YposKesi
  • 9.2.18 FinVector
  • 9.2.19 Resilience
  • 9.2.20 Novartis Gene Therapies